Cidofovir Diphosphate Inhibits Adenovirus 5 DNA Polymerase via both Nonobligate Chain Termination and Direct Inhibition, and Polymerase Mutations Confer Cidofovir Resistance on Intact Virus

• Published in: Antimicrobial agents and chemotherapy Vol. 63; no. 1
• Main Authors: Chamberlain, Jeffrey M, Sortino, Katherine, Sethna, Phiroze, Bae, Andrew, Lanier, Randall, Bambara, Robert A, Dewhurst, Stephen
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.01.2019
• Subjects: Adenovirus Infections, Human - virology; Adenoviruses, Human; Adenoviruses, Human - drug effects; Adenoviruses, Human - enzymology; Adenoviruses, Human - genetics; Adenoviruses, Human - isolation & purification; Antiviral Agents; Antiviral Agents - pharmacology; Cidofovir; Cidofovir - pharmacology; Cytosine; Cytosine - analogs & derivatives; Cytosine - metabolism; Cytosine - pharmacology; DNA Primers - chemical synthesis; DNA Primers - genetics; DNA, Viral; DNA, Viral - antagonists & inhibitors; DNA, Viral - biosynthesis; DNA, Viral - genetics; DNA-Directed DNA Polymerase; DNA-Directed DNA Polymerase - genetics; DNA-Directed DNA Polymerase - metabolism; Dose-Response Relationship, Drug; Humans; Kinetics; Mutation; Organophosphonates; Organophosphonates - metabolism; Organophosphonates - pharmacology; Real-Time Polymerase Chain Reaction; Recombinant Proteins - genetics; Recombinant Proteins - metabolism; Viral Proteins; Viral Proteins - genetics; Viral Proteins - metabolism; Virus Replication - drug effects; Virus Replication - genetics; DNA polymerase; antiviral agents; adenoviruses
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/AAC.01925-18

Human adenovirus (AdV) can cause fatal disease in immune-suppressed individuals, but treatment options are limited, in part because the antiviral cytidine analog cidofovir (CDV) is nephrotoxic. The investigational agent brincidofovir (BCV) is orally bioavailable, nonnephrotoxic, and generates the same active metabolite, cidofovir diphosphate (CDVpp). However, its mechanism of action against AdV is poorly understood. Therefore, we have examined the effect of CDVpp on DNA synthesis by a purified adenovirus 5 (AdV5) DNA polymerase (Pol). CDVpp was incorporated into nascent DNA strands and promoted a nonobligate form of chain termination (i.e., AdV5 Pol can extend, albeit inefficiently, a DNA chain even after the incorporation of a first CDVpp molecule). Moreover, unlike a conventional mismatched base pair, misincorporated CDVpp was not readily excised by the AdV5 Pol. At elevated concentrations, CDVpp inhibited AdV5 Pol in a manner consistent with both chain termination and direct inhibition of Pol activity. Finally, a recombinant AdV5 was constructed, containing Pol mutations (V303I and T87I) that were selected following an extended passage of wild-type AdV5 in the presence of BCV. This virus had a 2.1-fold elevated 50% effective concentration (EC ) for BCV and a 1.9-fold increased EC for CDV; thus, these results confirmed that viral resistance to BCV and CDV can be attributed to mutations in the viral Pol. These findings show that the anti-AdV5 activity of CDV and BCV is mediated through the viral DNA Pol and that their antiviral activity may occur via both (nonobligate) chain termination and (at high concentration) direct inhibition of AdV5 Pol activity.